Suppr超能文献

姜黄素对尼曼匹克 C1 型小鼠模型神经退行性变无效。

Lack of efficacy of curcumin on neurodegeneration in the mouse model of Niemann-Pick C1.

机构信息

Dept. of Pediatrics, University of Arizona, Tucson, AZ, 85724-5073, United States.

出版信息

Pharmacol Biochem Behav. 2012 Mar;101(1):125-31. doi: 10.1016/j.pbb.2011.12.009. Epub 2011 Dec 17.

Abstract

In order to determine the efficacy of curcumin in ameliorating symptoms of neurodegeneration in the mouse model of Niemann-Pick C1, a variety of formulations and dosages of curcumin, one comparable to one previously reported as efficacious, were provided orally to Npc1(-/-)mice. Plasma levels of curcumin, survival, tests of motor performance, and memory (in some cases) were performed. We found variable, but mild, increases in survival (1.5% to 18%). The greatest increased survival occurred with the highest dose (which was unformulated) while the control for the lipidated formulation (containing phosphatidylcholine and stearic acid) had an equivalent impact and other formulations, while not significantly increased, are also not statistically different in effect from the highest dose. We conclude that curcumin is not a highly efficacious treatment for neurodegeneration in Npc1(-/-) mice. Phosphatidylcholine and stearic acid should be studied further.

摘要

为了确定姜黄素在改善尼曼-匹克 C1 型小鼠模型神经退行性变症状中的疗效,我们以不同的配方和剂量给 Npc1(-/-) 小鼠口服姜黄素,其中一种配方和剂量与之前报道的有效剂量相当。我们检测了姜黄素的血药浓度、存活率、运动表现测试和记忆(在某些情况下)。我们发现,存活率有不同程度的轻度升高(1.5%至 18%)。最高剂量(未成型)组的存活率升高最大,而含磷脂酰胆碱和硬脂酸的脂质体配方对照组的效果相当,其他配方的效果虽没有明显升高,但与最高剂量相比,在统计学上也没有显著差异。我们的结论是,姜黄素不是治疗 Npc1(-/-) 小鼠神经退行性变的高效疗法。磷脂酰胆碱和硬脂酸应该进一步研究。

相似文献

1
Lack of efficacy of curcumin on neurodegeneration in the mouse model of Niemann-Pick C1.
Pharmacol Biochem Behav. 2012 Mar;101(1):125-31. doi: 10.1016/j.pbb.2011.12.009. Epub 2011 Dec 17.
3
Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium.
Nat Med. 2008 Nov;14(11):1247-55. doi: 10.1038/nm.1876. Epub 2008 Oct 26.
4
Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease.
PLoS One. 2016 Mar 28;11(3):e0152007. doi: 10.1371/journal.pone.0152007. eCollection 2016.
5
Neurological Dysfunction in Early Maturity of a Model for Niemann-Pick C1 Carrier Status.
Neurotherapeutics. 2016 Jul;13(3):614-22. doi: 10.1007/s13311-016-0427-5.
6
Developmental delay in motor skill acquisition in Niemann-Pick C1 mice reveals abnormal cerebellar morphogenesis.
Acta Neuropathol Commun. 2016 Sep 1;4(1):94. doi: 10.1186/s40478-016-0370-z.
8
Reduction of glutamate neurotoxicity: A novel therapeutic approach for Niemann-Pick disease, type C1.
Mol Genet Metab. 2021 Dec;134(4):330-336. doi: 10.1016/j.ymgme.2021.11.008. Epub 2021 Nov 16.

引用本文的文献

1
Organ Weights in Mutant Mice Partly Normalized by Various Pharmacological Treatment Approaches.
Int J Mol Sci. 2022 Dec 29;24(1):573. doi: 10.3390/ijms24010573.
2
Understanding and Treating Niemann-Pick Type C Disease: Models Matter.
Int J Mol Sci. 2020 Nov 26;21(23):8979. doi: 10.3390/ijms21238979.
3
Acidic Ca stores in neurodegeneration.
Messenger (Los Angel). 2016 Jun 1;5(1-2):37-55. doi: 10.1166/msr.2016.1054.
4
Relative efficacy of nicotinamide treatment of a mouse model of infantile Niemann-Pick C1 disease.
J Appl Genet. 2017 Feb;58(1):99-102. doi: 10.1007/s13353-016-0367-0. Epub 2016 Oct 25.
5
Diagnostic workup and management of patients with suspected Niemann-Pick type C disease.
Ther Adv Neurol Disord. 2016 May;9(3):216-29. doi: 10.1177/1756285616635964. Epub 2016 Mar 2.
6
Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease.
PLoS One. 2016 Mar 28;11(3):e0152007. doi: 10.1371/journal.pone.0152007. eCollection 2016.
8
Therapeutic potential of cyclodextrins in the treatment of Niemann-Pick type C disease.
Clin Lipidol. 2012 Jun;7(3):289-301. doi: 10.2217/clp.12.31.
9
Treatment of Niemann--pick type C disease by histone deacetylase inhibitors.
Neurotherapeutics. 2013 Oct;10(4):688-97. doi: 10.1007/s13311-013-0217-2.
10
Current controversies in Niemann-Pick C1 disease: steroids or gangliosides; neurons or neurons and glia.
J Appl Genet. 2013 May;54(2):215-24. doi: 10.1007/s13353-012-0130-0. Epub 2013 Jan 5.

本文引用的文献

1
SREBP2 mediates the modulation of intestinal NPC1L1 expression by curcumin.
Am J Physiol Gastrointest Liver Physiol. 2011 Jul;301(1):G148-55. doi: 10.1152/ajpgi.00119.2011. Epub 2011 Apr 28.
3
New agents and approaches to treatment in Niemann-Pick type C disease.
Curr Pharm Biotechnol. 2011 Jun;12(6):897-901. doi: 10.2174/138920111795542697.
4
Curcumin inhibits cholesterol uptake in Caco-2 cells by down-regulation of NPC1L1 expression.
Lipids Health Dis. 2010 Apr 19;9:40. doi: 10.1186/1476-511X-9-40.
7
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice.
Nature. 2009 Jul 16;460(7253):392-5. doi: 10.1038/nature08221. Epub 2009 Jul 8.
8
Curcumin upregulates transcription factor Nrf2, HO-1 expression and protects rat brains against focal ischemia.
Brain Res. 2009 Jul 28;1282:133-41. doi: 10.1016/j.brainres.2009.05.009. Epub 2009 May 13.
9
Curcumin disrupts the Mammalian target of rapamycin-raptor complex.
Cancer Res. 2009 Feb 1;69(3):1000-8. doi: 10.1158/0008-5472.CAN-08-2367. Epub 2009 Jan 27.
10
Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium.
Nat Med. 2008 Nov;14(11):1247-55. doi: 10.1038/nm.1876. Epub 2008 Oct 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验